India's Chemical and Pharma Sector Is Being Quietly Tested by the Hormuz Disruption
India's chemical and pharmaceutical industries sit at an unusual intersection of the Hormuz crisis. They are large enough to be materially affected by it, diversified enough to have some resilience, and strategically important enough that the Indian government has intervened directly in energy markets to protect their operations. But they are not large enough, or visible enough internationally, to be prominently discussed in Western coverage of the conflict's economic consequences.
This is an oversight that investors and procurement managers watching these sectors should correct.
The LPG Problem
Liquefied petroleum gas is the main cooking fuel for households and restaurants across India. It is also a chemical feedstock — particularly for the petrochemicals sector that underpins India's chemicals manufacturing base. India imports 60 percent of its LPG demand, most of which passes through the Strait of Hormuz. When the IRGC effectively closed the strait on February 28, LPG was the first fuel category in India to feel the impact — the wikipedia summary of the fuel crisis notes it was the "first fuel to be affected" — producing long queues and delayed deliveries across urban distribution networks.
The Indian government's response included importing piped gas connections to 580,000 new households in March alone, moving consumers toward domestically sourced gas networks that bypass the Hormuz exposure. It also raised export duties on diesel and aviation fuel to 21.5 rupees and 29.5 rupees per litre respectively, specifically to protect domestic availability.
For the chemicals sector, the LPG constraint translates directly into feedstock cost pressure for olefin production — the starting material for a wide range of plastics and industrial chemicals. India's chemicals industry was already navigating margin compression from Chinese competitive pressure. Higher feedstock costs in the current environment are not a tailwind.
The API Supply Chain: More Resilient Than It Looks
India's pharmaceutical sector — the world's largest generics supplier — is more insulated than the chemicals sector, and the reasons are instructive. Active pharmaceutical ingredient manufacturing in India relies primarily on chemical feedstocks sourced domestically or from China rather than from Gulf imports. The primary Hormuz-linked pressure on Indian pharma is indirect: higher energy costs for API manufacturing (primarily electricity and fuel for reactors and separation equipment) and higher logistics costs for export shipments taking longer routes.
These are real costs but not existential ones. Indian API manufacturers have been expanding domestic energy generation capacity — solar and renewable installations within manufacturing parks — and have been running inventory buffers above normal levels since the supply chain disruptions of 2020 to 2022. The institutional learning from COVID-era supply shocks has made the sector meaningfully more resilient.
The more significant risk is a second-order one: if the global food system is disrupted by fertilizer shortages and food inflation rises substantially, the political pressure on governments in Asia and Africa to control medicine prices typically increases. Price control environments are difficult for generic pharma companies, and India's exporters are sensitive to the regulatory policies of their major markets.
The Chemical Industry's Strategic Response
India's chemical industry associations have been lobbying for emergency customs duty waivers on key feedstocks and intermediates, and for priority access to LPG allocations for industrial users rather than allowing the domestic market to compete entirely on commercial terms with industrial buyers. These are the kinds of industrial policy decisions that typically move slowly — but the Hormuz crisis has compressed decision timelines across Indian government ministries.
The medium-term opportunity for India's chemical sector is worth noting alongside the near-term pressure. India's chemicals and petrochemicals industry has a multi-year ambition to capture market share from China in global chemical supply chains, backed by the Production Linked Incentive scheme and significant private investment. If the Gulf supply disruption persists long enough to force global buyers to restructure their feedstock and chemical intermediate sourcing, India is one of the credible alternative suppliers — particularly for specialty chemicals and intermediates. Crisis-driven supply chain diversification has historically created durable market share shifts. India's sector is positioned to capture some of that shift if it can navigate the near-term input cost pressure without losing the investment momentum it has been building.
The Medium-Term Opportunity
India's chemical sector — particularly the specialty chemicals and pharmaceutical ingredients segments — has an opportunity in the current disruption that requires careful positioning to capture. The crisis is forcing global buyers to reassess supply chain concentration risks that were previously acceptable because they were theoretical. China-plus-one sourcing strategies, which had been advancing steadily since 2018, are now being complemented by Gulf-plus-one strategies as buyers realise that their chemical intermediate and feedstock sourcing has a Hormuz dependency they hadn't fully mapped.
India's competitive strengths in chemicals are well-established: strong engineering talent, established regulatory compliance infrastructure (GMP certification for pharma, ISO and REACH for chemicals), competitive operating costs, and a government actively supporting the sector through PLI schemes and infrastructure investment. What has been missing is the external urgency that makes buyers commit to source diversification rather than simply discussing it. The Hormuz crisis may be providing that urgency in a way that trade policy and supply chain consultants never quite managed to.
The window for India to capture this structural shift is not unlimited. China's chemical industry is also adapting — seeking alternative feedstocks, diversifying its own import sourcing, and competing aggressively on price in markets where Indian suppliers are targeting. But for the specific categories where India has established technical credibility and regulatory acceptance — APIs, agrochemical intermediates, specialty dyes and pigments — the current period offers a genuine commercial opportunity to convert supply chain risk conversations into long-term customer relationships.